Imaging of [11C]erlotinib pharmacokinetics in non small cell lung cancer patients; an in vivo study with positron emission tomography
Recruiting
- Conditions
- lung cancer10038666
- Registration Number
- NL-OMON32923
- Lead Sponsor
- Vrije Universiteit Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 10
Inclusion Criteria
Patients age of 18-70 years
Patients with non small cell lung cancer planned to receive erlotinib
Life expectancy of at least 12 weeks
Malignant lesion of at least 1.5 cm diameter within the chest as measured by CT
Performance status Karnofsky index >60%
Laboratory requirements
Written informed consent
Exclusion Criteria
Claustrophobia
Pregnant or lactating patients
Patients having metal implants (e.g. pacemakers)
Concurrent or previous treatment with experimental drugs
Haemoglobin level < 6 mmol/l
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Primary study parameters/outcome of the study:<br /><br><br /><br>Change in [11C]erlotinib kinetics in EGFR mutated non small cell lung carcinoma<br /><br>(NSCLC) compared to non mutated EGFR NSCLC. </p><br>
- Secondary Outcome Measures
Name Time Method <p>Secundary study parameters/outcome of the study:<br /><br><br /><br>1. Validation of the PET-CT study<br /><br>2. Compare the venous and arterial plasma kinetics of [11C]erlotinib<br /><br>3. Study the relationship between tumor blood flow and [11C]erlotinib kinetics<br /><br>in tumor tissue</p><br>